Author: Vere Hodge, R Anthony
Title: Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA Document date: 2018_6_28
ID: tudwns0r_96
Snippet: Priscilla Yang is investigating the potential of the entry viral glycoprotein (E), mediating attachment and membrane fusion, as a suitable antiviral target for drugs against dengue. It has been confirmed that small molecules can interact with E to give activity in both a target-based assay and a cell culture antiviral assay. The next step is to validate E as an antiviral target in vivo. Although it is necessary to confirm antiviral activity, it i.....
Document: Priscilla Yang is investigating the potential of the entry viral glycoprotein (E), mediating attachment and membrane fusion, as a suitable antiviral target for drugs against dengue. It has been confirmed that small molecules can interact with E to give activity in both a target-based assay and a cell culture antiviral assay. The next step is to validate E as an antiviral target in vivo. Although it is necessary to confirm antiviral activity, it is also necessary to show that this approach can lead to antiviral compounds having a high genetic barrier to resistance. It was an encouraging start to find that some compounds did not show resistance up to passage 9. However, I think that Sophie Duraffour holds the record for ICAR's longest resistance test, with resistance to (S)-HPMPDAP appearing in two strains of camelpox virus after passaging 30 times, taking 18 months, before resistant clones could be obtained. (Sophie Duraffour, 22nd ICAR, 3-7 May in Miami Beach, FL, USA). To investigate resistance to dengue, Priscilla's group prepared various dengue mutant viruses containing point substitutions, which were chosen from naturally occurring E sequences identified in public databases. None of the current compounds were active against all these mutant strains. Surely, that suggests that, for these compounds, resistance will be a critical factor to be investigated.
Search related documents:
Co phrase search for related documents- antiviral activity and cell culture: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- antiviral activity and cell culture antiviral assay: 1, 2, 3, 4, 5, 6
- antiviral activity and critical factor: 1, 2, 3, 4
- antiviral activity and dengue drug: 1, 2
- antiviral activity and fusion membrane attachment: 1, 2, 3
- antiviral activity and genetic barrier: 1, 2, 3, 4
- antiviral activity and high resistance genetic barrier: 1, 2
- antiviral activity and membrane attachment: 1
- antiviral activity and mutant strain: 1, 2, 3
- antiviral activity and mutant virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- antiviral activity and public database: 1
- antiviral activity and resistance genetic barrier: 1, 2, 3
- antiviral activity and small molecule: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70
- antiviral activity and vivo antiviral target: 1, 2, 3
- antiviral assay and cell culture: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- antiviral assay and cell culture antiviral assay: 1, 2, 3, 4, 5, 6, 7, 8
- antiviral assay and small molecule: 1, 2, 3, 4, 5
- antiviral assay and vivo antiviral target: 1
- antiviral compound and cell culture: 1, 2, 3, 4, 5, 6, 7, 8, 9
Co phrase search for related documents, hyperlinks ordered by date